These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 22343334)

  • 81. Circulating lymphocyte subsets in different clinical situations after renal transplantation.
    van de Berg PJ; Hoevenaars EC; Yong SL; van Donselaar-van der Pant KA; van Tellingen A; Florquin S; van Lier RA; Bemelman FJ; ten Berge IJ
    Immunology; 2012 Jun; 136(2):198-207. PubMed ID: 22321054
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Biomarker assessment of the immunomodulator effect of atorvastatin in stable renal transplant recipients and hypercholesterolemic patients.
    Guillén D; Cofán F; Ros E; Millán O; Cofán M; Brunet M
    Mol Diagn Ther; 2010 Dec; 14(6):357-66. PubMed ID: 21047146
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [Immunological monitoring of the efficacy of extracorporeal photopheresis for prevention of kidney transplant rejection].
    Faenko AP; Chuksina YY; Zulkarnayev AB; Fedulkina VA; Vatazin AV; Kantaria RO
    Urologiia; 2020 Sep; (4):73-78. PubMed ID: 32897018
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Two-signal blockade with anti-CD45RB and anti-CD154 monoclonal antibodies inhibits graft rejection via CD4-dependent mechanisms in allogeneic skin transplantation.
    Kim EY; Lee EN; Lee J; Park HJ; Chang CY; Jung DY; Choi SY; Lee SK; Joh JW; Kim SJ
    Exp Mol Med; 2006 Jun; 38(3):284-94. PubMed ID: 16819287
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Clinical significance of CCR7
    Kim KW; Kim BM; Doh KC; Cho ML; Yang CW; Chung BH
    Sci Rep; 2018 Jun; 8(1):8827. PubMed ID: 29891963
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Altered proportions of naïve, central memory and terminally differentiated central memory subsets among CD4+ and CD8 + T cells expressing CD26 in patients with type 1 diabetes.
    Matteucci E; Ghimenti M; Di Beo S; Giampietro O
    J Clin Immunol; 2011 Dec; 31(6):977-84. PubMed ID: 21887518
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients.
    Ciancio G; Burke GW; Suzart K; Roth D; Kupin W; Rosen A; Olson L; Esquenazi V; Miller J
    Transplantation; 2002 Apr; 73(7):1100-6. PubMed ID: 11965039
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Efficacy and safety of daclizumab induction for primary kidney transplant recipients in combination with tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression.
    Ciancio G; Burke GW; Suzart K; Vaidya A; Roth D; Kupin W; Mattiazzi A; Rosen A; Esquenazi V; Miller J
    Transplant Proc; 2003 Mar; 35(2):873-4. PubMed ID: 12644172
    [No Abstract]   [Full Text] [Related]  

  • 89. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Post-transplant repopulation of naïve and memory T cells in blood and lymphoid tissue after alemtuzumab-mediated depletion in heart-transplanted cynomolgus monkeys.
    Marco MR; Dons EM; van der Windt DJ; Bhama JK; Lu LT; Zahorchak AF; Lakkis FG; Cooper DK; Ezzelarab MB; Thomson AW
    Transpl Immunol; 2013 Dec; 29(1-4):88-98. PubMed ID: 24120957
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis.
    Dalakas MC; Rakocevic G; Schmidt J; Salajegheh M; McElroy B; Harris-Love MO; Shrader JA; Levy EW; Dambrosia J; Kampen RL; Bruno DA; Kirk AD
    Brain; 2009 Jun; 132(Pt 6):1536-44. PubMed ID: 19454532
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Immune reconstitution following rabbit antithymocyte globulin.
    Gurkan S; Luan Y; Dhillon N; Allam SR; Montague T; Bromberg JS; Ames S; Lerner S; Ebcioglu Z; Nair V; Dinavahi R; Sehgal V; Heeger P; Schroppel B; Murphy B
    Am J Transplant; 2010 Sep; 10(9):2132-2141. PubMed ID: 20883548
    [TBL] [Abstract][Full Text] [Related]  

  • 93. A Decade of Experience With Alemtuzumab Therapy for Severe or Glucocorticoid-Resistant Kidney Transplant Rejection.
    van Vugt LK; van der Zwan M; Clahsen-van Groningen MC; van Agteren M; Hullegie-Peelen DM; De Winter BCM; Reinders MEJ; Miranda Afonso P; Hesselink DA
    Transpl Int; 2023; 36():11834. PubMed ID: 38020744
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis.
    Hill-Cawthorne GA; Button T; Tuohy O; Jones JL; May K; Somerfield J; Green A; Giovannoni G; Compston DA; Fahey MT; Coles AJ
    J Neurol Neurosurg Psychiatry; 2012 Mar; 83(3):298-304. PubMed ID: 22056965
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Immune reconstitution 20 years after treatment with alemtuzumab in a rheumatoid arthritis cohort: implications for lymphocyte depleting therapies.
    Cooles FA; Anderson AE; Drayton T; Harry RA; Diboll J; Munro L; Thalayasingham N; Östör AJ; Isaacs JD
    Arthritis Res Ther; 2016 Dec; 18(1):302. PubMed ID: 27993172
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Expansion of highly differentiated cytotoxic terminally differentiated effector memory CD8+ T cells in a subset of clinically stable kidney transplant recipients: a potential marker for late graft dysfunction.
    Yap M; Boeffard F; Clave E; Pallier A; Danger R; Giral M; Dantal J; Foucher Y; Guillot-Gueguen C; Toubert A; Soulillou JP; Brouard S; Degauque N
    J Am Soc Nephrol; 2014 Aug; 25(8):1856-68. PubMed ID: 24652799
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Exhaustion of CD8
    Leonhard J; Schaier M; Kälble F; Zeier M; Steinborn A
    Front Immunol; 2023; 14():1164284. PubMed ID: 37287988
    [TBL] [Abstract][Full Text] [Related]  

  • 98. TIGIT regulates apoptosis of risky memory T cell subsets implicated in belatacept-resistant rejection.
    Sun H; Hartigan CR; Chen CW; Sun Y; Tariq M; Robertson JM; Krummey SM; Mehta AK; Ford ML
    Am J Transplant; 2021 Oct; 21(10):3256-3267. PubMed ID: 33756063
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Pathogen Stimulation History Impacts Donor-Specific CD8(+) T Cell Susceptibility to Costimulation/Integrin Blockade-Based Therapy.
    Badell IR; Kitchens WH; Wagener ME; Lukacher AE; Larsen CP; Ford ML
    Am J Transplant; 2015 Dec; 15(12):3081-94. PubMed ID: 26228897
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Progressive Loss of Donor-Reactive CD4
    van der List ACJ; Litjens NHR; Klepper M; Prevoo F; Betjes MGH
    J Immunol; 2022 Oct; 209(7):1389-1400. PubMed ID: 36165198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.